Drug lookup
Drug reference

Gatifloxacin

Fluoroquinolone · Antibiotic

FluoroquinoloneAntibiotic
CDSCO withdrawnSchedule H1
EXCRETION
not curated
INTERACTIONS
12 major
incl. contraindicated
PREGNANCY
not curated
Top interactionssee all 12
  • CisaprideContraindicatedDatabaseDDInter
  • AbarelixSevereDatabaseDDInter
  • AbirateroneSevereDatabaseDDInter
  • AcarboseSevereDatabaseDDInter

Mechanism

The quinolone antibiotics target bacterial DNA gyrase and topoisomerase IV. For many gram-positive bacteria, topoisomerase IV is the primary target, while for many gram-negative microbes, DNA gyrase is the primary target. Inhibition of these enzymes prevents the continuous introduction of negative supercoils into DNA and the separation of interlinked daughter DNA molecules, which are crucial for bacterial DNA replication and transcription.

Indications

Ophthalmic infectionsRespiratory Tract Infections (due to activity against S. pneumoniae and other respiratory pathogens)Bacterial conjunctivitis (ophthalmic preparation only, systemic use withdrawn)conjunctivitiskeratitisgram positive coccal (mainly respiratory and ENT) infections

Dosing

Adult
bioavailable; the oral dose (450 mg) is higher than the IV (300 mg). All fluoroquinolones are widely distributed in body fluids and tissues (see Table 46– 1). Serum half­lives range from 3 to 10 hours. The relatively long half­lives of levofloxacin, gemifloxacin, and moxifloxacin permit once­daily dosing. Oral absorption is impaired by divalent and trivalent cations, including those in antacids.…

Pharmacokinetics

Bioavailability
High bioavailability (systemic forms)
Excretion
Renal elimination

Contraindications

  • Q-T prolongation
  • arrhythmias
  • phototoxicity
  • unpredictable hypoglycaemia

Side effects

Serious
  • Hypoglycemia
  • Hypoglycemia (systemic forms, led to withdrawal for systemic use)
  • Hyperglycemia (systemic forms, led to withdrawal for systemic use)
  • Q-T prolongation
  • arrhythmias
  • phototoxicity
  • unpredictable hypoglycaemia

Drug interactions

Cisapride
Contraindicated
Database

Significantly increased risk of QT interval prolongation and Torsades de Pointes, leading to potentially fatal arrhythmias.

Concomitant use is contraindicated. Avoid this combination.

Source: DDInter

Abarelix
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Abiraterone
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Acarbose
Severe
Database

Drug interaction classified as: antagonism

Source: DDInter

Acetohexamide
Severe
Database

Drug interaction classified as: antagonism

Source: DDInter

Adenosine
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Albiglutide
Severe
Database

Drug interaction classified as: antagonism

Source: DDInter

Alfuzosin
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Alimemazine
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Alogliptin
Severe
Database

Drug interaction classified as: antagonism

Source: DDInter

Aminolevulinic Acid
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Amiodarone
Severe
Database

Drug interaction classified as: synergy.

Source: DDInter

Related guidelines

Other Fluoroquinolone drugs

Ask House about Gatifloxacin

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: KD Tripathi 7e, Goodman & Gilman 14e, Katzung·Verified: 2026-05-13 · House clinical team